A

Amgen

Makes biotech medicines for serious illnesses

Process Analytical Engineer

Full-TimeUpdated on 10/24/2026
$88.3k - $119.4k
Junior, Mid
Bachelor's, Master's, Associate's
Holly Springs, NC, USA
In PersonOn-site role; domestic and international travel may be required.
Biology & BiotechRegulatory & Quality (Life Sciences)

About the job

Requirements
  • A Master's degree, or a Bachelor's degree and 2 years of cGMP laboratory, analytical instrument validation, and/or Process Engineer experience, or an Associate's degree and 6 years of such experience, or a high school diploma/GED and 8 years of such experience.
  • Laboratory experience in a cGMP laboratory environment, including exposure to analytical instrument validation.
  • Knowledge of the methodology, instrumentation, and analytical techniques used for biopharmaceutical testing.
  • Understanding of current regulatory requirements for cGMP laboratory equipment validation and electronic record integrity.
  • Ability to provide on-call support coverage nights and weekends on a rotating basis.
  • Strong written and verbal skills and the ability to work with minimum direction.
  • Demonstrated interpersonal and facilitation skills and ability to work in a collaborative, team-based environment.
  • Ability to apply analytical skills to evaluate and interpret sophisticated problems using multiple sources of information.
  • Ability to function within cross-functional teams and embrace a team-based environment.
  • Work schedule flexibility as required to support 24/7 operations.
  • Ability for domestic and international travel.
Responsibilities
  • Plan, execute, and document qualification, calibration, and routine maintenance of laboratory systems for cGMP Quality Control laboratory facilities.
  • Troubleshoot analytical and laboratory systems and perform root cause analysis; coordinate vendor support and repairs; execute and track calibration, maintenance, and requalification activities through the Computerized Maintenance Management System (CMMS) Maximo; and support manufacturing operations to improve equipment uptime and reliability.
  • Author, own, and approve Validation Life Cycle documents for computer-related systems, including Data Integrity testing and business administration of laboratory computer-related systems.
  • Support commissioning, qualification, validation, and system lifecycle documentation to maintain compliance and operational readiness.
  • Partner with manufacturing teams to resolve issues, improve system reliability, and minimize operational downtime.
  • Work with the capital project team to ensure systems are installed and operate safely, comply with environmental health and safety practices, rules, and regulations, and meet global engineering and design requirements.
  • Serve as System Owner and Business Administrator for analytical equipment.
  • Lead or work with teams in the design, development, and selection of new systems, instruments, calibration capabilities, and consumable components.
  • Develop laboratory equipment specifications for procurement of new laboratory equipment and instruments.
  • Maintain current working knowledge of regulatory requirements for equipment qualification and calibration.
  • Support generation and resolution of protocol discrepancies as required.
  • Alert Quality Control Management if equipment fails to meet calibration or qualification requirements and conduct impact assessments and investigations as required.
  • Lead the development of calibration and maintenance programs, ensure spare-part availability, schedule repairs and maintenance, and coordinate maintenance execution to keep systems in proper working order and minimize disruption to laboratory activities.
  • Participate in technical project teams as a subject matter expert on instrument validation regulations and procedures.
  • Evaluate current and potential supplier capabilities and assess new technologies that could provide cost savings, throughput, or other unique capabilities to manufacturing.
  • Write or contribute to equipment operating procedures and manuals.
  • Design and conduct training for manufacturing staff and other department staff as applicable.
  • Own and project-manage change controls while meeting applicable change control metrics.
  • Prepare and present periodic management updates on activities to senior management.
  • Conduct periodic reviews of instrument validation as part of the validation lifecycle.
  • Contribute to Data Integrity Assessments for laboratory systems.
  • Support laboratory systems validation and Data Integrity practices during audit interactions.
  • Support additional tasks and projects as assigned by management.
  • Develop, coordinate, analyze, and present results for operational issues and engineering projects.
  • Provide technical support for commercial and clinical manufacturing as needed.
  • Complete tasks under the general direction of lead engineers to complete design and engineering within schedule and budget constraints.
  • Identify, support, and/or lead implementation of engineering-based improvements or upgrades in small to medium scope and complexity.
  • Ensure necessary commissioning and qualification of systems is completed in alignment with site GMP requirements and support interactions with regulatory inspectors as necessary.
  • Apply basic engineering principles and practices in support of daily operation, maintenance, and troubleshooting of plant and process systems.
  • Monitor systems to identify performance risks and implement risk-reduction strategies.
  • Provide troubleshooting support to reduce production downtime, including leading and/or supporting technical root cause analysis and implementation of corrective and preventive action; support may be required outside normal working hours, including nights, weekends, and holidays.
  • Support new product and technology introductions by performing engineering assessments, implementing equipment modifications, and supporting engineering runs.
  • Advance condition-based and predictive maintenance practices by incorporating advanced data analytics where applicable.
  • Lead investigations of abnormal conditions through deviation and related business processes.
Desired Qualifications
  • Bachelor's degree in engineering or a related technical field.
  • Demonstrated success in managing an equipment qualification or maintenance program.

About the company

Amgen develops and makes biologic medicines, which are drugs built from proteins and antibodies grown in living cells, for serious conditions such as heart disease, cancer, and bone loss. Its anemia drug Epogen, approved in 1989, became one of the biotechnology industry's first blockbuster medicines. Amgen grows these drugs in large tanks called bioreactors, and its products include the cholesterol drug Repatha, the bone-building drug Evenity, and the severe asthma drug Tezspire. It earns money by selling these medicines, mostly through large drug wholesalers that supply hospitals and pharmacies. Amgen was founded in 1980 and is based in Thousand Oaks, California.

Company Size

10,001+

Company Stage

IPO

Headquarters

Thousand Oaks, California

Founded

1980

Get referred to Amgen

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Growth is broad-based: 22 products grew at least 10%, lifting June 2026 quarter revenue 10% to $10.1 billion.
  • Stock grants gained value: Amgen shares rose 27% from January to October 9, 2026, versus 10% for rival Eli Lilly.
  • Many U.S. roles are remote: 145 of Amgen's 615 U.S. job openings in October 2026 were fully remote.

What critics are saying

  • Its 2025 best seller is shrinking: cheaper copies cut bone drug Prolia's sales 32% in the June 2026 quarter.
  • MariTide, Amgen's obesity bet, faces a giant: Lilly's Mounjaro and Zepbound outsold all of Amgen in the June 2026 quarter.
  • Most tech openings are in India: 156 of Amgen's 210 information systems jobs in October 2026 were in Hyderabad.

What makes Amgen unique

  • It copies rivals' blockbusters too: Pavblu, its version of Regeneron's eye drug Eylea, sold $700 million in 2025.
  • Amgen hunts drug targets in a nation's DNA: its Icelandic unit deCODE has genetic data on two-thirds of Iceland's adults.
  • Amgen opened a U.S. cancer-drug class: Blincyto, approved in 2014, was the first to tether immune cells to cancer.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Professional Development Budget
  • Conference Attendance Budget

Company News

PR Newswire
Oct 26th, 2026
Amgen appoints former Yum! Brands CEO David Gibbs to its board

Amgen has appointed David W. Gibbs to its board of directors, effective immediately. He will serve on the Audit Committee and the Compensation and Management Development Committee. Gibbs recently retired as president and chief executive officer of Yum! Brands, owner of Taco Bell and Kentucky Fried Chicken. As chief executive from 2020 to 2025, he led its digital transformation and expanded it to nearly 61,000 locations. He has sat on the board of Under Armour since 2021 and PepsiCo since 2026. "His experience creating direct relationships with customers will help inform how we prepare for future launches," said Robert A. Bradway, Amgen's chairman and chief executive officer. The board now has 13 directors, 12 of them independent.

Yahoo Finance
Oct 26th, 2026
ESMO 2026: Moderna vaccine debate, Roche's $3.6B KRAS bet and Amgen's lung cancer data

Three cancer drug trials drew attention at the European Society for Medical Oncology (ESMO) meeting, with investors and analysts weighing the results. Moderna and Merck's vaccine intismeran autogene cut the relative risk of melanoma recurrence or death by 42% in a Phase 3 trial. Moderna's shares have still fallen by double digits since the results leaked early, as investors question its valuation and the vaccine's manufacturing and commercial potential. Roche's divarasib reduced the risk of death or disease progression by 42% in KRAS G12C lung cancer, beating Krazati and Lumakras. Patients lived a median of about 18 months, versus a year. Roche raised its peak sales forecast from 3.6 billion Swiss francs to 3 billion. Amgen's Imdelltra, combined with Imfinzi, cut the risk of death by 58% in small cell lung cancer. Median survival was 21.1 months, against 12.7 months for Imfinzi alone.

Yahoo Finance
Oct 25th, 2026
Amgen vs Gilead: Which biotech dividend stock is the better buy, with yields of 2.2% and 2.1%?

Amgen and Gilead Sciences, two of the few big biotech companies that pay dividends, suit different kinds of income investors, according to a comparison by The Motley Fool's Keith Speights. Amgen offers a forward dividend yield above 2.2%, against slightly below 2.1% for Gilead. Gilead has the lower payout ratio, at 43.5% versus 60.9%, and the cheaper valuation: 15.6 times forward earnings against 16.7. Amgen's product sales grew 9% year over year in its latest quarter, against 8% for Gilead. It has 17 drugs on track to be blockbusters this year, versus eight for Gilead, and 29 late-stage programs. Speights favours Amgen for yield and growth, and Gilead for safety and value.

Yahoo Finance
Oct 24th, 2026
Amgen vs Johnson & Johnson: cheaper Amgen edges J&J's $94.2B revenue giant on valuation

A Motley Fool comparison of Amgen and Johnson & Johnson (J&J) favours Amgen, mainly on price. Amgen's forward price-to-earnings ratio is 19.4x, against 24.1x for J&J. In 2025, Amgen's revenue rose about 10% to $36.7 billion, with net income of $7.7 billion. J&J's revenue grew 6% to $94.2 billion, with net income of $26.8 billion and free cash flow of $19.7 billion. Amgen carries far more debt: its debt-to-equity ratio is nearly 6.3x, against about 0.6x for J&J. Three wholesalers account for 77% of its gross revenues. Amgen also struck a deal with the US government that exempts it from pharmaceutical tariffs for three years in return for price cuts on two drugs. J&J expects revenue of $101 billion this fiscal year, and Amgen expects about $37.8 billion.

Yahoo Finance
Oct 22nd, 2026
Eli Lilly vs Amgen: $65.2B revenue and 45% growth against a cheaper stock for 2026

Eli Lilly is growing far faster than Amgen, but investors pay a steep premium for it. The article's author favours Lilly for long-term investors in 2026. Lilly's FY 2025 revenue rose 45% to about $65.2 billion, with net income of $20.6 billion and a 32% net margin. Amgen's revenue grew about 10% to $36.7 billion, with net income of $7.7 billion and a 21% margin. Lilly trades at a forward P/E of 38.3x against Amgen's 19.4x. Its debt-to-equity ratio is about 1.6x, compared with nearly 6.3x for Amgen. Lilly's growth rests on its GLP-1 drugs Zepbound and Mounjaro. The article projects 2026 revenue of $88.7 billion, against about $37.8 billion for Amgen.